India consults on data requirements for drug trials, BA/BE studies
This article was originally published in SRA
India's Central Drugs Standard Control Organization has issued a draft guideline explaining proposed requirements for submission of chemical and pharmaceutical information, including stability study data, for the approval of clinical trial and bio-availability/bio-equivalence studies1.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.